Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2006 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Information provided by:
Hadassah Medical Organization Identifier:
First received: October 3, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted

Patients with Central Retinal Vein Occlusion will undergo vitrectomy, a small needle of about 71 micron will enter a branch retinal vein and TPA will be injected into the obstracted vein.

Condition Intervention
Central Retinal Vein Occlusion
Procedure: Retinal endo vascular surgery

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Visual acuity
  • Amount of macular edema.

Estimated Enrollment: 10
Study Start Date: October 2006
Estimated Study Completion Date: October 2007
Detailed Description:

Patients with Central Retinal Vein Occlusion less than 6 month duration and reduction of vision to 6/21 will go OCT and FANG examinations.

Patient will be operated vitrectomy, and a branch retinal vein will be punctured by small needle and rTPA 200mcg/ml will be injected to the vein.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • crvo less than 6 month
  • Visual Acuity less than 6/21
  • No prior eye surgery except cataract.

Exclusion Criteria:

  • Retinal/iris neovascularization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00383773

Contact: Michael Halpert, MD. 00972507874385
Contact: Hadas Lemberg, PhD 0097226777572

Sponsors and Collaborators
Hadassah Medical Organization
Study Chair: Michael halpert Hadassah Medical Organization
  More Information

No publications provided Identifier: NCT00383773     History of Changes
Other Study ID Numbers: 1yumbo-HMO-CTIL
Study First Received: October 3, 2006
Last Updated: October 3, 2006
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
retinal vein occlusion

Additional relevant MeSH terms:
Retinal Vein Occlusion
Cardiovascular Diseases
Embolism and Thrombosis
Eye Diseases
Retinal Diseases
Vascular Diseases
Venous Thrombosis processed this record on November 25, 2014